The Xmn1 polymorphic site 5′ to the Gγ gene and its correlation to the Gγ:Aγ ratio, age at first blood transfusion and clinical features in β-Thalassemia patients from Western Iran

[1]  B. Bain.  Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management , 2011 .

[2]  P. Landais,et al.  Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia , 2007, Transfusion.

[3]  P. Vicari,et al.  XmnI polymorphism is associated with fetal hemoglobin levels in hypoplastic syndromes. , 2006, Sao Paulo medical journal = Revista paulista de medicina.

[4]  M. Sutton,et al.  Pharmacological Induction of Fetal Hemoglobin: Why Haven't We Been More Successful in Thalassemia? , 2005, Annals of the New York Academy of Sciences.

[5]  A. Bahador,et al.  Management of thalassemia major by partial splenectomy , 1994, Pediatric Surgery International.

[6]  E. Rachmilewitz,et al.  MEDICAL PROGRESS : β-thalassemia , 2005 .

[7]  R. Ware,et al.  Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. , 2004, Blood.

[8]  P. Vossough,et al.  Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening , 2004, Annals of Hematology.

[9]  Z. Rahimi,et al.  β‐Globin gene cluster haplotypes in sickle cell patients from southwest Iran , 2003, American journal of hematology.

[10]  S. Thein,et al.  Evidence of genetic interaction between the beta-globin complex and chromosome 8q in the expression of fetal hemoglobin. , 2002, American journal of human genetics.

[11]  H. Yarmohammadi,et al.  β-THALASSEMIA INTERMEDIA FROM SOUTHERN IRAN: IVS-II-1 (G→A) IS THE PREVALENT THALASSEMIA INTERMEDIA ALLELE , 2002, Hemoglobin.

[12]  D. Mohanty,et al.  Molecular pathogenesis and clinical variability of β‐thalassemia syndromes among Indians , 2001 .

[13]  U. Dasgupta,et al.  Variable severity of β-thalassemia patients of Eastern India: effect of α-thalassemia and XmnI polymorphism , 2001, Clinical and Experimental Medicine.

[14]  Y. Saunthararajah,et al.  Advances in experimental treatment of β-thalassaemia , 2001 .

[15]  F. Pourfarzad,et al.  THE β-THALASSEMIA MUTATION SPECTRUM IN THE IRANIAN POPULATION , 2001, Hemoglobin.

[16]  Y. Saunthararajah,et al.  Advances in experimental treatment of beta-thalassaemia. , 2001, Expert opinion on investigational drugs.

[17]  E. Rachmilewitz,et al.  New trends in the treatment of -thalassemia , 2000 .

[18]  E. Rachmilewitz,et al.  New trends in the treatment of b-thalassemia , 2000 .

[19]  E. Vichinsky,et al.  Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia , 1999, American journal of hematology.

[20]  T. Spector,et al.  A candidate gene study of F cell levels in sibling pairs using a joint linkage and association analysis. , 1999 .

[21]  D. Mohanty,et al.  Variable clinical severity of Hb E beta-thalassemia among Indians. , 1999, The Journal of the Association of Physicians of India.

[22]  Prescott,et al.  High prevalence of low bone mass in thalassaemia major , 1998, British journal of haematology.

[23]  E. Bakker.  Methods in Molecular Medicine: Molecular Diagnosis of Genetic Diseases , 1997 .

[24]  F. Costa,et al.  Successful use of hydroxyurea in beta-thalassemia major. , 1997, The New England journal of medicine.

[25]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[26]  H. Bard,et al.  Association of -158(C → T) (XmnI) DNA Polymorphism inGγ-Globin Promoter with Delayed Switchover from Fetal to Adult Hemoglobin Synthesis , 1997, Pediatric Research.

[27]  A. Schechter,et al.  Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. , 1996, Blood.

[28]  J. Old.  Hemoglobinopathies : community clues to mutation detection. , 1996, Methods in molecular medicine.

[29]  F. Barton,et al.  Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. , 1995, Controlled clinical trials.

[30]  M L Terrin,et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.

[31]  M. Vidaud,et al.  A comprehensive scanning method for rapid detection of β‐globin gene mutations and polymorphisms , 1992, Human mutation.

[32]  E. Rappaport,et al.  The Xmn I site (-158, C----T) 5' to the G gamma gene: correlation with the Senegalese haplotype and G gamma globin expression. , 1991, Hemoglobin.

[33]  T. Huisman,et al.  DNA sequence variation associated with elevated fetal G gamma globin production. , 1985, Blood.

[34]  R. Schneider.  Differentiation of electrophoretically similar hemoglobins--such as S, D, G, and P; or A2, C, E, and O--by electrophoresis of the globin chains. , 1974, Clinical chemistry.

[35]  J. Clegg,et al.  An Improved Method for the Characterization of Human Haemoglobin Mutants: Identification of α2β295GLU, Haemoglobin N (Baltimore) , 1965, Nature.